What are the recommendations for managing pregnancy in a woman with systemic lupus erythematosus?

Managing Pregnancy in Systemic Lupus Erythematosus

Hydroxychloroquine should be continued preconceptionally and throughout pregnancy in all women with SLE, combined with low-dose aspirin for those at risk of pre-eclampsia (especially with lupus nephritis or positive antiphospholipid antibodies), and heparin added for those with definite antiphospholipid syndrome. 1

Preconception Counseling and Risk Stratification

Pregnancy should only be attempted when SLE has been stable and inactive for at least 6 months on pregnancy-compatible medications. 1, 2, 3

Critical preconception assessments include:

• Disease activity status: Active disease at conception significantly increases maternal and fetal complications 1, 2
• Renal function: History of lupus nephritis or current proteinuria ≥500 mg increases risk 1, 4
• Antiphospholipid antibody status: Determines need for anticoagulation during pregnancy 1
• Anti-Ro/SSA and anti-La/SSB antibodies: Associated with 0.7-2% risk of congenital heart block 1
• Medication review: Switch from teratogenic drugs (mycophenolate, methotrexate, leflunomide, cyclophosphamide) to pregnancy-compatible alternatives before conception 1

Medication Management During Pregnancy

Safe Medications Throughout Pregnancy

Hydroxychloroquine is the cornerstone of SLE pregnancy management and should be continued in all patients to prevent flares and improve obstetrical outcomes 1. Additional safe options include:

• Oral glucocorticoids, azathioprine, cyclosporin A, and tacrolimus can be used to prevent or manage SLE flares 1
• Low-dose aspirin (LDA) should be started preconceptionally or no later than 16 weeks gestation in women with lupus nephritis or positive antiphospholipid antibodies 1
• Low molecular weight heparin (LMWH) combined with LDA is required for women with definite antiphospholipid syndrome 1

Managing Disease Flares

For moderate-to-severe flares during pregnancy:

• High-dose glucocorticoids including intravenous pulse therapy 1
• Intravenous immunoglobulin 1
• Plasmapheresis (also useful for refractory nephrotic syndrome) 1
• Cyclophosphamide should never be used in the first trimester (fetal loss OR 25.5) and reserved only for severe, life-threatening manifestations in second or third trimester 1

Strictly Contraindicated Medications

Mycophenolic acid, methotrexate, leflunomide, and first-trimester cyclophosphamide must be avoided due to teratogenicity 1

Disease Activity Monitoring During Pregnancy

Monthly assessment of disease activity using validated indices, renal function parameters, and serological markers is essential 1. Specific monitoring includes:

Renal Monitoring

• Urine protein excretion, urine sediment analysis (glomerular hematuria, urinary casts), and serum creatinine/GFR 1
• Renal activity strongly correlates with adverse pregnancy outcomes 1

Serological Monitoring

• Declining C3/C4 levels (even within normal range) and rising anti-dsDNA titers indicate disease exacerbation rather than pre-eclampsia 1
• Smaller increases in C3 from first to second/third trimester associated with increased risk of pregnancy loss, intrauterine growth restriction, and preterm birth 1

Common pitfall: Pregnancy physiological changes can mimic SLE symptoms—distinguish true flares using serological markers 1

Fetal Surveillance Protocol

Routine Ultrasonographic Screening

• First trimester (11-14 weeks): Baseline assessment 1
• Second trimester (20-24 weeks): Doppler sonography has good negative predictive value for placental disorders 1

Third Trimester Intensive Monitoring

Monthly Doppler sonography of umbilical artery, uterine arteries, ductus venosus, and middle cerebral artery to screen for placental insufficiency and small-for-gestational-age fetuses 1

Critical distinction: For late intrauterine growth restriction (after 34 weeks), umbilical artery Doppler alone is insufficient—must assess abdominal circumference growth velocity and cerebroplacental ratio 1

Fetal Echocardiography

Recommended for suspected fetal dysrhythmia or myocarditis, especially in anti-Ro/SSA or anti-La/SSB positive mothers 1. However, routine intensive monitoring (weekly/biweekly 16-26 weeks) for all anti-Ro/La-positive women without previous congenital heart block has unclear cost-effectiveness given the low 0.7-2% risk 1

Important caveat: Fluorinated steroids for incomplete congenital heart block lack established efficacy in large cohorts 1

Adjunct Supplementation

Calcium, vitamin D, and folic acid supplementation should be provided as in the general population, with particular attention to those receiving glucocorticoids and/or heparin due to detrimental bone effects 1. Measure vitamin D levels after pregnancy confirmation 1

Contraception Considerations

For women not planning pregnancy:

• Intrauterine devices can be offered to all SLE/APS patients without gynecological contraindications 1
• Combined hormonal contraceptives only in stable/inactive SLE with negative antiphospholipid antibodies 1
• Progesterone-only contraception must be carefully weighed against thrombosis risk in antiphospholipid antibody-positive women 1